Emma Yasinski

I am a freelance science and medical journalist, fascinated by how the scientific process leads to incredible discoveries, but also can lead to publication bias leaning toward positive findings and minimizing negatives. With a bachelor’s degree in neuroscience from Lafayette College and a Master’s in Science and Medical Journalism from Boston University, I’ve written about clinical trial transparency, organ donation, and basic molecular biology for publications like The Scientist, The Atlantic, Undark.org, Kaiser Health News, and more. At MedShadow, I research and write about the sometimes unexpected ways that medicines can affect us, and what we can do if and when it does.

A now world-wide outbreak of hepatitis ‘that began in fall 2021 among young children, sickening hundreds, continues nearly eight months later, as of May 2022. The medical community is searching for its cause.  Some researchers believe it may have been triggered by COVID-19 infections or by colds or other viruses. The challenge is that the term hepatitis denotes an inflammation of the liver, but in order to treat it, a doctor needs to know what caused that inflammation. That’s problematic, because a doctor must know the cause to treat it effectively. Here’s what you need to know about the many…

Read More

Two recently authorized antiviral drugs designed to protect against the most severe outcomes of COVID-19 may be game-changers during the ongoing pandemic. Those benefits may come at a cost, however. It’s crucial that you and your healthcare providers understand these drugs’ potential side effects, so you use them as safely as possible. “Obviously, if you’ve got a serious case of COVID, you need to be treated,” despite the risk of side effects says Katherine Seley-Radtke, PhD, professor of chemistry and biochemistry at the University of Maryland, Baltimore County. How Effective Are They? Both drugs, Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir and…

Read More